Skip to content
Tuesday, November 17, 2026 · Today’s edition, 6:30 a.m. ETTue, Nov 17 · 6:30 a.m. editionSign inMy Desk 0EditionsSign in
IHEISharesINDEX

iShares U.S. Pharmaceuticals ETF

$109.64-1.25% vs prior close
8111152-WK

Price through Nov 16, 2026 · Flows through Nov 13, 2026. Figures use the latest available records, not a live quote. Fund details retrieved Nov 16, 2026. Holdings snapshot retrieved Nov 16, 2026.

The fund generally will invest at least 80% of its assets in the component securities of its underlying index and in investments that have economic characteristics that are substantially identical to the component securities of its underlying index. The underlying index measures the performance of the pharmaceuticals sector of the U.S. equity market. The underlying index includes pharmaceutical companies such as manufacturers of prescription or over-the-counter drugs or vaccines. The fund is non-diversified.

IHE price

Source: Market tape, daily closes; price return, distributions not reinvested
Table
DateIHE close
Aug 17, 2026$103.08
Aug 18, 2026$105.31
Aug 19, 2026$108.16
Aug 20, 2026$105.72
Aug 21, 2026$106.79
Aug 24, 2026$106.80
Aug 25, 2026$107.41
Aug 26, 2026$105.93
Aug 27, 2026$104.73
Aug 28, 2026$103.96
Aug 31, 2026$103.64
Sep 1, 2026$103.98
Sep 2, 2026$105.16
Sep 3, 2026$105.42
Sep 4, 2026$104.68
Sep 8, 2026$102.68
Sep 9, 2026$102.19
Sep 10, 2026$101.27
Sep 11, 2026$101.07
Sep 14, 2026$101.81
Sep 15, 2026$100.89
Sep 16, 2026$101.23
Sep 17, 2026$102.27
Sep 18, 2026$101.53
Sep 21, 2026$102.24
Sep 22, 2026$102.92
Sep 23, 2026$101.32
Sep 24, 2026$102.34
Sep 25, 2026$102.53
Sep 28, 2026$103.19
Sep 29, 2026$102.26
Sep 30, 2026$100.52
Oct 1, 2026$99.00
Oct 2, 2026$98.65
Oct 5, 2026$98.22
Oct 6, 2026$98.34
Oct 7, 2026$99.39
Oct 8, 2026$98.86
Oct 9, 2026$100.09
Oct 12, 2026$100.19
Oct 13, 2026$97.36
Oct 14, 2026$99.49
Oct 15, 2026$101.12
Oct 16, 2026$101.06
Oct 19, 2026$100.58
Oct 20, 2026$103.47
Oct 21, 2026$102.78
Oct 22, 2026$104.78
Oct 23, 2026$102.51
Oct 26, 2026$102.81
Oct 27, 2026$103.35
Oct 28, 2026$103.67
Oct 29, 2026$106.61
Oct 30, 2026$107.61
Nov 2, 2026$106.92
Nov 3, 2026$106.72
Nov 4, 2026$109.09
Nov 5, 2026$105.57
Nov 6, 2026$106.60
Nov 9, 2026$109.67
Nov 10, 2026$110.46
Nov 11, 2026$111.08
Nov 12, 2026$110.25
Nov 13, 2026$111.03
Nov 16, 2026$109.64

Weekly net flows, 3M

Net outflow over the range: −$12M

  • Inflow / above zero
  • Outflow / below zero
Aug 10Aug 17Aug 24Aug 31Sep 7Sep 14Sep 21Sep 28−$73.9MOct 5Oct 12Oct 19Oct 26Nov 2+$17.1MNov 9Aug 10Aug 24Sep 7Sep 21−$73.9MOct 5Oct 19+$17.1MNov 9Aug 10Sep 7−$73.9MOct 5+$17.1MNov 9
Source: Daily creation and redemption records
Show as table
LabelValue ($)
Aug 10$5.1M
Aug 17$42.2M
Aug 24$822.5K
Aug 31−$31.1M
Sep 7$0
Sep 14$35.5M
Sep 21−$10.2M
Sep 28−$144K
Oct 5−$73.9M
Oct 12−$29M
Oct 19−$21.3M
Oct 26$5.4M
Nov 2$47.9M
Nov 9$17.1M
The desk’s read

Money keeps arriving — +$49M of net inflows over the past month, about 2.8% of the fund's asset base, while the price has returned +29.2% so far this year. At 0.37% a year it is not the cheapest way in — IWM has a reported fee of 0.19%.

COMPOSED FROM THE FUND’S OWN DAILY RECORDS · UPDATED WITH EACH REFRESH

$1.7Bassets under management
0.37%expense ratio · $37 per $10,000 a year
+$49Mnet flow, trailing month
270Kavg daily volume, 30 days
52holdings · US-domiciled
2006listed May 1, 2006 · beta 0.41
The book at a glance
LLY-0.8%JNJ-1.1%VTRS-0.4%ZTS+0.7%RPRX-1.1%PFE-0.1%MRK-2.2%BMY-0.8%JAZZ-0.7%ELAN-1.4%CORT-5.1%AXSM-3.3%LGND-2.3%SUPN-3.0%

CELL SIZE IS PORTFOLIO WEIGHT · COLOR IS THE CHANGE IN THE LATEST AVAILABLE SNAPSHOT · TOP 40 POSITIONS

Holdings
#HoldingWeightPriceDay52-wk
1LLYELI LILLY26.59%$1431.67-0.8%
2JNJJOHNSON & JOHNSON22.16%$282.55-1.1%
3VTRSVIATRIS4.85%$20.74-0.4%
4ZTSZOETIS4.74%$84.39+0.7%
5RPRXROYALTY PHARMA4.74%$68.53-1.1%
6PFEPFIZER4.31%$28.86-0.1%
7MRKMERCK & CO4.15%$144.46-2.2%
8BMYBRISTOL MYERS SQUIBB4.08%$62.93-0.8%
9JAZZJAZZ PHARMACEUTICALS3.18%$239.77-0.7%
10ELANELANCO ANIMAL HEALTH2.71%$26.41-1.4%
11CORTCORCEPT THERAPEUTICS1.41%$69.22-5.1%
12AXSMAXSOME THERAPEUTICS1.28%$137.01-3.3%
13LGNDLIGAND PHARMACEUTICALS1.25%$301.71-2.3%
14SUPNSUPERNUS PHARMACEUTICALS1.25%$28.83-3.0%
15LQDALIQUIDIA0.86%$56.37-1.8%

The full book, free with one sign-in.

Top 15 positions are open to everyone. Sign in once and every fund’s complete holdings — plus watchlists and flow alerts — unlock across the network.

Sign in to see all 52

Sector weights

  • Health Care99.89%
  • Pharmaceuticals99.85%
  • Cash and/or Derivatives0.15%
Source: Portfolio composition, latest disclosure
Show as table
ItemValue (%)
Health Care99.89%
Pharmaceuticals99.85%
Cash and/or Derivatives0.15%
Performance
1 week-0.7%
1 month+8.5%
3 months+6.8%
6 months+24.8%
YTD+29.2%
1 year—
3 years—

PRICE RETURN, DISTRIBUTIONS NOT REINVESTED

Net flows
1 week+$61M
1 month+$49M
3 months−$17M
YTD+$578M
1 year+$722M

CREATION/REDEMPTION DOLLARS, DAILY RECORDS

Monthly net flows

  • Inflow / above zero
  • Outflow / below zero
+$113.1MNov+$50.4MDec+$101.7MJan+$35.9MFeb−$4.4MMar−$65MApr−$80MMay+$637.2MJul−$13.7MAug+$14.9MSep−$113.8MOct+$65MNovNovDecJanFebMarAprMay+$637.2MJulAugSepOct+$65MNovNovJanMarMay+$637.2MAug+$65MNov
Source: Daily creation/redemption records, trailing twelve months
Show as table
LabelValue ($)
Nov$113.1M
Dec$50.4M
Jan$101.7M
Feb$35.9M
Mar−$4.4M
Apr−$65M
May−$80M
Jul$637.2M
Aug−$13.7M
Sep$14.9M
Oct−$113.8M
Nov$65M
The risk read
26%realized volatility, 30 days (annualized)
19%realized volatility, 1 year
-10.0%deepest fall from a peak, 1 year
-1.3%latest close versus that peak

The top holding is 26.6% of the book; the top ten carry 82%. Spread across 56+ names, it behaves like roughly 7 equally-weighted positions.

VOLATILITY & DRAWDOWN FROM THE DAILY TAPE · CONCENTRATION FROM THE LATEST DISCLOSED BOOK

Options tape
12calls · latest snapshot
—puts · latest snapshot
—put/call ratio
154Kshares traded
Most-traded holdings, options premiumBullishBearish
LLY ELI LILLY$43M$45M
JNJ JOHNSON & JOHNSON$6M$7M
MRK MERCK & CO$6M$5M
BMY BRISTOL MYERS SQUIBB$2M$2M
LQDA LIQUIDIA$1M$2M

TODAY’S OPTIONS PREMIUM IN THE FUND’S UNDERLYING NAMES

The case against IHE

Due diligence cuts both ways. These funds sit on the same shelf and beat IHE on at least one dimension that matters — the fee, the asset base, or where the money is going.

FundFeeAssetsFlow, 1MThe case
SPDW SPDR Portfolio Developed World ex-US ETF0.03%$41.6B+$917M-34bp on fee · 24× the assets · +$917M in over the monthHead-to-head
SPMD State Street SPDR Portfolio S&P 400 Mid Cap ETF0.03%$18.4B+$199M-34bp on fee · 11× the assets · +$199M in over the monthHead-to-head
IJH iShares Core S&P Mid-Cap ETF0.05%$123.7B+$109M-32bp on fee · 71× the assets · +$109M in over the monthHead-to-head
IDEV iShares Core MSCI International Developed Markets ETF0.04%$34B+$587M-33bp on fee · 20× the assets · +$587M in over the monthHead-to-head
IGSB iShares 1-5 Year Investment Grade Corporate Bond ETF0.04%$23.7B+$422M-33bp on fee · 14× the assets · +$422M in over the monthHead-to-head
Sign in to save this to The RecordA timestamped copy for the file — documentation, not advice.

Watch & listen: IShares

From the manager behind IHEAll of Watch & Listen
ETF Dailyfrom Private Wealth Daily

ETF launches, fund research, and market coverage in your inbox every morning. Free.

Free. Every morning. Unsubscribe from any edition in one click.